ISIN
CH0009115129
Ticker
KNRS
Sector
Sub-Industry
Country
Switzerland
Year Founded
2017
Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.
Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.
Recently, in response to the global challenge of COVID-19, Kinarus has initiated clinical evaluation of its combination therapy to treat patients suffering from SARS-CoV-2 infection. Kinarus has discovered that KIN001 has anti-viral activity against SARS-CoV-2, including against its variants of concern. KIN001 also possesses anti-inflammatory and anti-fibrotic activity.
Worldwide
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
25.04.2024 | None | Non-Executive member | Buy | CHF 1.11 |
31.10.2023 | None | Executive member | Sell | CHF 4,248.75 |
07.09.2023 | None | Executive member | Sell | CHF 11,713.02 |
23.06.2023 | None | Executive member | Sell | CHF 45,028.85 |
13.06.2023 | None | Executive member | Sell | CHF 38,761.94 |
05.06.2023 | None | Executive member | Sell | CHF 1,417,143.65 |
02.06.2022 | None | Executive member | Buy | CHF 7,441,035.53 |
02.06.2022 | None | Non-Executive member | Buy | CHF 2,483,942.78 |
02.06.2022 | None | Executive member | Buy | CHF 922,192.69 |
02.06.2022 | None | Executive member | Buy | CHF 399,716.30 |
CH0009115129
506700VDL70GGMHR5758
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.